TY - JOUR
T1 - FluCyD combination in low-grade lymphomas
T2 - An active regimen for selected patients
AU - Siracusano, Licia
AU - Balzarotti, Monica
AU - Magagnoli, Massimo
AU - Castagna, Luca
AU - Ripa, Cristina
AU - Nozza, Andrea
AU - Torri, Walter
AU - Sarina, Barbara
AU - Isa, Luciano
AU - Bertuzzi, Alexia
AU - Timofeeva, Inna
AU - Morenghi, Emanuela
AU - Santoro, Armando
PY - 2004/7
Y1 - 2004/7
N2 - A phase-two trial evaluating the synergistic activity and toxicity of fludarabine, cyclophosphamide and dexamethasone (FluCyD) in untreated and pre-treated low-grade lymphoproliferative disorders is presented. Patients were given fludarabine 20 mg/m2 on days 1-5, cyclophosphamide 1000 mg/m2 on day 1, dexamethasone 20 mg on days 1-5, every four weeks for a maximum of six courses in untreated cases, and for four courses in pre-treated cases allocated to high-dose consolidation. One patient refused high dose program for persistent disease, and was treated with rituximab. A total of 29 patients were included. The overall response rate was 89%, with actuarial three-year disease free survival and overall survival 56% and 72%, respectively. Haematological toxicity was limited, and main complications of therapy were infections: one patient died of Jacob-Creutzfeld virus encephalitis after FluCyD and rituximab and three other cases, with concomitant or subsequent autoimmune disease requiring immunosuppression, developed central nervous system infection. Nine patients were scheduled to mobilize progenitor cells with chemotherapy and G-CSF. Only two patients mobilized an adequate amount of CD34+, while in two further cases bone marrow harvest was performed, but the product was considered inadequate in one. One patient died after mobilization chemotherapy, because of haemolytic anaemia complicated with acute renal failure. Despite its effectiveness in indolent lymphoproliferative disorders, the incidence of infections, as well as the impact of fludarabine on subsequent peripheral blood stem cell mobilization, suggest that more careful selection criteria must applied before patients are allocated to this regimen.
AB - A phase-two trial evaluating the synergistic activity and toxicity of fludarabine, cyclophosphamide and dexamethasone (FluCyD) in untreated and pre-treated low-grade lymphoproliferative disorders is presented. Patients were given fludarabine 20 mg/m2 on days 1-5, cyclophosphamide 1000 mg/m2 on day 1, dexamethasone 20 mg on days 1-5, every four weeks for a maximum of six courses in untreated cases, and for four courses in pre-treated cases allocated to high-dose consolidation. One patient refused high dose program for persistent disease, and was treated with rituximab. A total of 29 patients were included. The overall response rate was 89%, with actuarial three-year disease free survival and overall survival 56% and 72%, respectively. Haematological toxicity was limited, and main complications of therapy were infections: one patient died of Jacob-Creutzfeld virus encephalitis after FluCyD and rituximab and three other cases, with concomitant or subsequent autoimmune disease requiring immunosuppression, developed central nervous system infection. Nine patients were scheduled to mobilize progenitor cells with chemotherapy and G-CSF. Only two patients mobilized an adequate amount of CD34+, while in two further cases bone marrow harvest was performed, but the product was considered inadequate in one. One patient died after mobilization chemotherapy, because of haemolytic anaemia complicated with acute renal failure. Despite its effectiveness in indolent lymphoproliferative disorders, the incidence of infections, as well as the impact of fludarabine on subsequent peripheral blood stem cell mobilization, suggest that more careful selection criteria must applied before patients are allocated to this regimen.
KW - Chemotherapy
KW - Fludarabine
KW - Low grade lymphomas
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=4043171185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4043171185&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:4043171185
VL - 7
SP - 357
EP - 362
JO - HAEMA
JF - HAEMA
SN - 1108-2682
IS - 3
ER -